SCHEMBL30588239

SCHEMBL30588239

COC(=O)C1CCC(n2ccc3c(Br)cccc32)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ HTT P42858 1/20 0.38
▸ CREBBP Q92793 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ PKM P14618 2/20 0.35
▸ SLC6A4 P31645 2/20 0.35
▸ SLC6A3 Q01959 2/20 0.35
▸ GLA P06280 1/20 0.35
▸ MAPT P10636 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ GAA P10253 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ KDM1A O60341 1/20 0.33
▸ OPRM1 P35372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31611542 0.87 POLB (0.41) ALDH1A1SMN1; SMN2HTTKDM4EPKM
SCHEMBL26122492 0.84 SYK (0.36) KDM4ENPC1RAB9AMEN1KMT2A
SCHEMBL26122489 0.84 SYK (0.36) KDM4ENPC1RAB9AMEN1KMT2A
SCHEMBL23648384 0.82 OPRM1 (0.36) KDM4ESLC6A4OPRM1OPRD1OPRK1
SCHEMBL26684361 0.75 L3MBTL3 (0.39) KDM4ESLC6A4
SCHEMBL31611389 0.75 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2HTTSLC6A4SLC6A3
SCHEMBL31611384 0.75 GRM7 (0.33) SLC6A4OPRM1OPRD1OPRK1
SCHEMBL26118122 0.75 GRM2 (0.37) SLC6A4SLC6A2OPRM1OPRD1OPRK1
SCHEMBL31611219 0.75 GRM2 (0.37) SLC6A4SLC6A2OPRM1OPRD1OPRK1
SCHEMBL26118124 0.75 GRM2 (0.37) SLC6A4SLC6A2OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-06-26 — — US disclosed
EP-4499628-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-02-05 — — EP disclosed
WO-2023180388-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS CRBN, AR, GNRHR ALDH1A1 3146/4885SMN1; SMN2 3919/4885HTT 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback